Predictive Oncology Inc. (NASDAQ:POAI – Free Report) – Investment analysts at HC Wainwright issued their Q3 2024 earnings per share estimates for Predictive Oncology in a research note issued on Monday, August 19th. HC Wainwright analyst S. Ramakanth expects that the medical instruments supplier will earn ($0.32) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. HC Wainwright also issued estimates for Predictive Oncology’s Q4 2024 earnings at ($0.26) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.05 EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.25 EPS and FY2028 earnings at $0.43 EPS.
Predictive Oncology Stock Up 6.1 %
NASDAQ:POAI opened at $0.97 on Tuesday. Predictive Oncology has a 1-year low of $0.85 and a 1-year high of $4.70. The firm’s 50-day moving average price is $1.08 and its 200-day moving average price is $1.80.
Hedge Funds Weigh In On Predictive Oncology
About Predictive Oncology
Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.
Recommended Stories
- Five stocks we like better than Predictive Oncology
- How to Start Investing in Real Estate
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- What is the S&P 500 and How It is Distinct from Other Indexes
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Predictive Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Predictive Oncology and related companies with MarketBeat.com's FREE daily email newsletter.